$FMC Corp (FMC.US)$ interesting upcoming ipo. Late stage for...

$FMC Corp (FMC.US)$ interesting upcoming ipo. Late stage for Non-Muscle invasive bladder cancer

The company is evaluating cretostimogene as a monotherapy in BOND-003, its ongoing Phase 3 trial in high-risk BCG-unresponsive NMIBC patients, and expects to report topline data by the end of 2024